OBJECTIVES: This study aimed to quantify the preferences of people with latent tuberculosis infection (LTBI) when making decisions on whether to accept preventive treatment with Isoniazid and to understand the trade-off nature of their decisionmaking. METHODS: English-speaking adults with LTBI were recruited from the tuberculosis (TB) clinic at British Columbia Centre for Disease Control. A customdesigned discrete choice experiment (DCE) measured preferences for 6 attributes of preventive treatment decision-making. A conditional logit model was performed to estimate respondents' preferences. RESULTS: Among the 152 participants, 142 (93.4%) with valid DCE responses were included for data analyses. Their average age was 38.2 years (SD = 12.6) and 62.7% were female. 85.9% of our respondents were born outside Canada and 71.8% were ethnically from Asian areas. Effectiveness of the preventive treatment (Risk of developing active TB after treatment, -0.23, p < 0.001), Risk of developing liver damage (-0.16, p < 0.001), Length of treatment (-0.05, p < 0.001), Risk of developing skin rash (-0.03, p = 0.002), and Risk of developing fatigue (-0.03, p = 0.009) were significant determinants of respondents' choices of preventive treatment. The negative preference estimates revealed that respondents were averse to higher risk of developing active TB, higher risk of developing liver damage, skin rash and fatigue, and longer period of treatment. Frequency of clinic visit was not a significant factor. Respondents' preferences varied according to their socio-demographic characteristics, past experiences of TB, BCG vaccination status, and the reason for tuberculin skin test. CONCLUSIONS: The results suggest that respondents were consistently in favor of LTBI preventive treatment with higher effectiveness, less side effects and shorter length.
Guo, N., Marra, F., Marra, C., Elwood, K., & FitzGerald, M. (2011). PRS34 EVALUATING PEOPLE’S PREFERENCES FOR PREVENTIVE TREATMENT OF LATENT TUBERCULOSIS INFECTION USING A DISCRETE CHOICE EXPERIMENT. Value in Health, 13(3), A201–A202. https://doi.org/10.1016/s1098-3015(10)72987-9